CD137

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Biopsy, NSCLC, Entrepreneurship, Carcinoma, DLL4, Patient, Neoplasm, PET, Merck, G&A, Doctor of Philosophy, MD, Insurance, IND, Mesothelioma, Research and development, CD137, Therapy, Paclitaxel, BTC, CRC, Melanoma, Stage 2, PD-L1, FDA, SCLC, PD-1, Pharmaceutical industry

Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.

Key Points: 
  • Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.
  • BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2023 financial results and provided business update.
  • The increase was primarily attributable to higher stock compensation expense of $1.0 million offset by lower insurance costs of $0.3 million.
  • During 2023, the Company decreased its cash position by $34.1 million, primarily from $40.6 million of net cash used in operating activities.

Crescendo Biologics to present at the 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024
Archery, Therapy, Immunotherapy, Dynamics (music), Section 3, PSMA, AACR, PST, Publication, CD137, AJ

Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, will be presenting two poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.

Key Points: 
  • Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing therapeutics, will be presenting two poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
  • Archer, S et al, CB307: A dual targeting costimulatory Humabody® VH therapeutic for treating PSMA-positive tumors, Poster Section 3, Abstract #5313
    Pierce, AJ et al, CB699: A novel mesothelin-binding Humabody® CD40 and CD137 dual-agonist for enhancing immune cell responses against MSLN+ tumors, Poster Section 3, Abstract #5302
    Both posters will be presented in the Immune Modulation Employing Agonist or Co-Stimulatory Approaches Session, on Tuesday 9 April 2024, 1:30 pm - 5:00 pm PST, and will be made available on the Publications section of the company’s website following their presentation at the meeting.

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

Retrieved on: 
Wednesday, February 28, 2024
Therapy, AstraZeneca, CMO, CD25, Biotechnology, Roche, Neoplasm, Physician, Obesity, Amgen, Icon, Pharmaceutical medicine, Bladder cancer, Royal college, ADC, Antibody, NHS, Safety, CB1, CSPC, Patient, CD137, Faculty, Partnership, Pharmaceutical industry

NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).

Key Points: 
  • NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO).
  • Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity.
  • “We are pleased to welcome Dominic to the Corbus team and look forward to benefitting from his experience in developing novel oncology therapeutics including ones that specifically target Nectin-4", said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Previously, Dr. Smethurst worked as a consultant advising biopharma companies, providing guidance on clinical development strategies and licensing projects.

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

Retrieved on: 
Wednesday, February 28, 2024
FDA, Therapy, R&D, MD, IND, Doctor of Philosophy, CD137, PD-1, PD-L1, Pharmaceutical industry

CTX-8371 is a fully-human, tetravalent bispecific antibody, discovered and developed by Compass Therapeutics as a next generation checkpoint blocker.

Key Points: 
  • CTX-8371 is a fully-human, tetravalent bispecific antibody, discovered and developed by Compass Therapeutics as a next generation checkpoint blocker.
  • The data highlighted the unique mechanism-of-action of CTX-8371, inducing dual blockade of PD-1 and PDL-1 and cleavage of cell surface PD-1.
  • In addition, CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings.
  • “These compelling data are a testament to the functionality of our novel checkpoint inhibitor and we are excited to continue evaluating its potential in clinical studies.

Bicycle Therapeutics to Present at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Cancer, Neoplasm, Publication, CD137, Abstract, AACR

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the acceptance of three abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego on April 5-10.
  • Title: Modulation of the natural killer cell immune response to tumor with a synthetic tumor-immune cell agonist, NK-TICA™
    Title: Tumor-targeted activation of CD137 using Bicycles: New insights into mechanism of action and discovery of BT7455, a clinical candidate for the treatment of EphA2-expressing cancers
    The posters will be made available in the Publications section of bicycletherapeutics.com following the presentations.

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 20, 2024
Biotechnology, General Health, Pharmaceutical, Health, Toxicity, Growth, Ovarian cancer, Radiopharmaceutical, Patient, Anal cancer, Bicycle, McKinsey & Company, Head, Cervical cancer, EV, Neoplasm, ATM, Therapy, Food and Drug Administration, TNBC, Net, Former, CMC, Thromboxane A2, Immune system, NSCLC, MUC, Peripheral neuropathy, SunOpta, Safety, Ovary, Participation, Knowledge, Novartis, Lazard, BRC, FDA, Cancer, Food, Pembrolizumab, Government, ADC, Brentuximab vedotin, CD137, Pharmaceutical industry

Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent corporate updates.
  • We continue to demonstrate our ability to develop highly differentiated, precision-guided therapeutics that may offer greater tolerability and lead to enhanced benefit for patients,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics.
  • Validating the company’s Bicycle® Radio Conjugates (BRC™) pipeline and partner for success, with updates expected from its wholly owned BRC program by mid-2024.
  • Advancing the company’s Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) immune-oncology pipeline through innovative partnerships.

Compass Therapeutics Provides Corporate Update

Retrieved on: 
Friday, January 5, 2024
Patient, CRC, Stage 2, IND, FDA, BTC, Research and development, PD-1, DLL4, CD137, PET, Melanoma, MD, Doctor of Philosophy, Therapy, Mesothelioma, Paclitaxel, Carcinoma, SCLC, Safety, Development, NSCLC, PD-L1, Pharmaceutical industry

As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.

Key Points: 
  • As previously disclosed, effective January 9, 2024, Vered Bisker-Leib, PhD, Compass President and COO, will lead Compass as Compass Chief Executive Officer and join the Compass board of directors.
  • Effective January 9, 2024, Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and Chief Executive Officer will transition to President of Research and Development and be appointed Vice Chair of the Compass board of directors.
  • BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported a business update.
  • Thomas Schuetz, MD, PhD, Compass’ Scientific Founder and current Chief Executive Officer will transition to President of Research and Development and assume the role of Vice Chair of the Compass board of directors.

Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC

Retrieved on: 
Wednesday, December 6, 2023
Patient, Dynamics (music), CD137, University, Toxicity, Safety, Therapy, Pharmaceutical industry

Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC

Key Points: 
  • Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC
    Crescendo expands trial of lead programme first-in-class, bispecific Humabody®, CB307 beyond Europe with first US trial site, the Fred Hutchinson Cancer Centre, at the University of Washington
    Cambridge, UK, 6 December 2023 – Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces that the first patients in the U.S. have been dosed as part of the ongoing Phase 1b study of CB307, Crescendo’s lead programme in PSMA+ metastatic castration-resistant prostate cancer (mCRPC).
  • CB307 is a first-in-class, half-life extended, CD137 x PSMA bispecific Humabody®, designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity.
  • The ongoing dose expansion part of the Phase 1b POTENTIA trial ( NCT04839991 ) comprises two cohorts, assessing the safety and efficacy of CB307 as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).
  • The US part of the trial has seen patients successfully dosed in both the monotherapy and combination cohorts at the Fred Hutchinson Cancer Centre.

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, MT1-MMP, Peripheral neuropathy, Brain, Safety, Immune system, Cervical cancer, Food, Therapy, Toxicity, Head, Diabetic neuropathy, Nobel Prize, Patient, CD137, Bicycle, FDA, Non-small-cell lung cancer, Pembrolizumab, Neoplasm, Ionis, Investigational New Drug, Brentuximab vedotin, MUC, ORR, Ovary, Anal cancer, Cancer, Ovarian cancer, Toxic leukoencephalopathy, Pain, R, Drug combination, EV, Central nervous system, TNBC, NSCLC, BRC, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Thromboxane A2

“In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.

Key Points: 
  • “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.
  • BT8009 is a Nectin-4 Bicycle toxin conjugate (BTC®) designed to overcome the significant toxicity associated with other toxin conjugate approaches.
  • Over 2024, Bicycle Therapeutics intends to generate early human imaging data from its wholly owned BRC pipeline.
  • Bicycle Therapeutics will continue to develop Bicycle® molecules to address disease outside of oncology through innovative partnerships.

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Patient, Pancreatic cancer, Ki-67 (protein), AACR, Amphetamine, Biomarker, AMP, Vaccine, Antigen, CD4, Lymph, CD137, Conference, KRAS, Phenotype, Development, CD8, Mouse, SITC, Tissue, Immunotherapy, Granzyme, Neoplasm, Risk, Research and development, Annual general meeting, Flow cytometry, RFS, V600E, Cancer, Therapy, CpG, Death, Peptide, BRAF, Pharmaceutical industry, Amphiphile, Research, Doctor of Philosophy

The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.

Key Points: 
  • The strength of the induced T cell response correlated with a significantly reduced risk of relapse and death.
  • The data will be presented at the Society for Immunotherapy of Cancer 38th Annual Meeting (SITC 2023) taking place at the San Diego Convention Center in San Diego, CA and virtually from November 1-5, 2023.
  • ELI-002 2P consists of 2 Amph-modified mKRAS peptide antigens, Amph-G12D and Amph-G12R (Amph-Peptides 2P), and an Amph-modified immune-stimulatory oligonucleotide adjuvant (Amph-CpG-7909).
  • 90% of immune responders had T cell responses to ≥ two mKRAS antigens, with 35% responding to all seven mKRAS antigens evaluated.